" BioVaxys Technology Corp. (CSE:BIOV) and BioElpida sign exclusive agreement to begin ovarian cancer vaccine bioproduction

BioVaxys Technology (BIOV) has signed the definitive exclusive bioproduction agreement with BioElpida S.A.S. (BioElpida) of Lyon, France.